Alpha Teknova, Inc. manufactures critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. The company operates two primary product categories: Lab Essentials, comprising research-use-only catalog and custom formulations, and Clinical Solutions, offering GMP-grade custom products for therapeutic and diagnostic applications. Key product types include pre-poured media plates for cell growth and cloning, liquid microbial culture media and supplements, and molecular biology reagents for sample manipulation and purification. Alpha Teknova serves pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions. The company’s modular manufacturing platform supports applications in cell and gene therapy, mRNA vaccines, liquid biopsy, genomics, and synthetic biology. Founded in 1996 by Genentech scientist Ted Davis, Alpha Teknova provides custom, made-to-order products with short turnaround times, supporting customers from early discovery through commercialization.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage teknova.com
Sector Healthcare IR page ir.teknova.com
Tags
cell and gene therapy, molecular diagnostics, mrna vaccines, custom reagents, microbial culture media, molecular biology reagents, pre-poured media plates, gmp manufacturing, synthetic biology, liquid biopsy, genomics, bioproduction, Lab Essentials, Clinical Solutions, Fill•Tek Dispensing System, Build•Tek Custom Configurator, AAV●Tek Solutions, AAV•Tek PCR Sample Prep Kit, AAV•Tek AAV Stabilizer, AAV•Tek AEX Buffer Screening Kit, Bacterial Culture Media, Yeast and Fungal Culture Media, Buffers and Reagents, Alcohol Solutions, Antibiotic Solutions, Biological Buffers, Chaotropic Agents, Molecular Biology Solutions, Surfactants and Detergents, Cryopreservation Media, Custom Manufacturing, Iodixanol Gradient Ultracentrifugation, Cesium Chloride Density Gradient Ultracentrifugation
Press page —

Metrics

Valuation  
Market cap $ 477.953M
Market cap (USD) $ 477.953M
P/E -31.79
PEG —
P/BV 7.99
P/S 10.40
P/OCF -85.81
P/FCF -74.87
Dividend yield —
Turnover / mcap —
Returns  
ROE -22.8%
ROI -21.1%
ROIC -15.5%
Profit margin -42.6%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 22.2%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 8
Quality score -37.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 40.52M 37.745M 36.684M 41.42M 36.893M 0
Net profit -17.259M -26.745M -36.78M -47.468M -9.803M 0
Free cash flow -9.794M -13.516M -26.748M -55.549M -28.946M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 3.8 8.35 3.73 5.64 20.48 —
Price performance 12m -0.54 1.24 -0.34 -0.72 — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 4.62M 4.67M 4.26M 3.95M 4.31M 4.62M
↳ YoY growth +0.9% -8.7% -7.3% +9.2% +7.1%
↳ 5y CAGR 0.0%
Borrowings, current (USD) — — — 0.00 0.00 4.05M 0.00
Borrowings, non-current (USD) — — — 22M 13.3M — —
Lease liabilities (USD) — — 20.5M 20.3M 17.2M 16.7M 15.1M
Cash and deposits (USD) 4.14M 3.32M 87.5M 42.2M 28.5M 3.71M 5.91M
Intangible assets (USD) — 19.9M 18.7M 17.6M 14.2M 13.1M 11.9M
Right-of-use assets (USD) — — 20.3M 19.7M 16.5M 15.8M 14.1M
Net debt (borrowings + leases - cash) (USD) — — — 74,000 1.97M 17M 9.23M
Cash flow detail
Operating cash flow (USD) — 2.51M -9.07M -27.4M -18.8M -12.4M -8.65M
Purchases of property, plant and equipment (USD) — -5.47M -19.9M -28.1M -7.93M -1.13M -1.15M
Change in receivables (cash effect) (USD) — -2.35M -278,000 380,000 292,000 -494,000 -374,000
Change in inventories (cash effect) (USD) — -987,000 -2.25M -7.55M 330,000 244,000 -2.37M
Change in payables (cash effect) (USD) — 867,000 270,000 572,000 -773,000 -594,000 470,000
Interest paid (cash effect) (USD) — -36,000 -414,000 -101,000 -1.75M -1.55M -1.46M
Income taxes paid (cash effect) (USD) — -323,000 -8,000 0.00 0.00 -39,000 -2,000
Share-based compensation (USD) — 300,000 1.55M 3.71M 4.14M 3.67M 3.43M
Operating cash flow before change in receivables (USD) — 4.86M -8.79M -27.8M -19.1M -11.9M -8.27M
Free cash flow (OCF - PPE - intangibles) (USD) — -2.96M -28.9M -55.5M -26.7M -13.5M -9.79M
Income detail
Research and development expense (USD) — 1.51M 4.31M 7.74M 5.57M 2.76M 2.2M
↳ 5y CAGR +7.8%
Total comprehensive income (USD) — 3.56M -9.81M -47.5M — — —
Provision for credit losses (USD) — -12,000 235,000 25,000 21,000 130,000 68,000
Credit cost ratio (credit losses / average receivables) (%) — — 5.1% 0.6% 0.5% 3.1% 1.5%
Reported Aug 13, 2021 Mar 18, 2022 May 12, 2022 Aug 11, 2023 Aug 13, 2024 Mar 7, 2025 Mar 2, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Teknova Reports Third Quarter 2026 Financial Results Bull 4 Bear 4 Results

Third quarter 2026 total revenue was $12.7 million, up 22% over the same quarter prior year

Company raises 2026 revenue guidance to $46-48 million

Strengthened balance sheet with $46 million public equity offering completed in October 2026

HOLLISTER, Calif., November 4, 2026 – Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30, 2026.

“We posted record revenue for the second consecutive quarter,” said Stephen Gunstream, President and Chief Executive Officer at Teknova. “Growth was driven by increased sales of products to life science tools and diagnostics, and to biopharma customers.

October 21, 2026 at 6:30 PM EDT

PDF Version

HOLLISTER, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2026, on Wednesday, November 4, 2026, following the close of market.

Teknova will host a webcast and conference call on Wednesday, November 4, 2026, beginning at 6:00 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to participate in the call, please register for the webcast here to receive a unique PIN number and dial-in information. The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Teknova Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in genomics, molecular diagnostics, and emerging therapeutic modalities. Our fast turnaround of high-quality agar plates, microbial culture and cryopreservation media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies.

Investor Contact Matt Lowell Chief Financial Officer [email protected] +1 831-637-1100

Media Contact Jennifer Henry Senior Vice President, Marketing [email protected] +1 831-313-1259

This press release was published by a CLEAR® Verified individual.

October 20, 2026 at 4:01 PM EDT

PDF Version

HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced in conjunction with its filing of a preliminary prospectus supplement, preliminary unaudited financial results for the three months ended September 30, 2026.

Set forth below are certain preliminary unaudited financial results for the three months ended September 30, 2026 and as of September 30, 2026:

  • Revenue for the three months ended September 30, 2026 is estimated to be within the range of $12.5 million and $12.7 million.

  • Gross margin for the three months ended September 30, 2026 is estimated to be within the range of 36.0% and 38.0%.

  • Adjusted EBITDA for the three months ended September 30, 2026 is estimated to be within the range of negative $1.2 million and negative $1 million.

  • Cash and short term investments as of September 30, 2026 is estimated to be $16.6 million.

Teknova’s total revenue is estimated to be up 19% to 21% compared to the same period in the prior year. Teknova’s gross margin is estimated to have expanded by 500-700 basis points compared to the same period in the prior year, driven primarily by top-line growth. Teknova’s estimated Adjusted EBITDA would represent an at least 25% improvement compared to the same period in the prior year, driven by continued cost discipline.

Teknova’s financial statements for the three months and nine months ended September 30, 2026 are not yet available. Accordingly, the information presented above reflects Teknova’s preliminary estimates subject to the completion of Teknova’s financial closing procedures and any adjustments that may result from the completion of the quarterly review of Teknova’s financial statements. As a result, these preliminary estimates may differ from the actual results that will be reflected in Teknova’s financial statements for the quarter when they are completed and publicly disclosed. These preliminary estimates may change and those changes may be material.

Teknova’s expectations with respect to its unaudited results for the periods discussed above are based upon management estimates and are the responsibility of management. Teknova’s independent registered public accounting firm has not audited, reviewed, or performed any procedures with respect to these preliminary results and, accordingly, does not express an opinion or any other form of assurance about them.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Teknova

Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in genomics, molecular diagnostics, and emerging therapeutic modalities. Our fast turnaround of high-quality agar plates, microbial culture and cryopreservation media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies.

Forward-Looking Statements

This press release contains forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding Teknova’s expectations on the availability of Teknova’s financial statements and completion of financial closing procedures. Forward-looking statements can often be identified by such words as "will," "expects," "plans," "believes," "intends," "estimates," "projects," "continue," "potential" or other similar words or expressions. Forward-looking statements are based on Teknova's current expectations. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks and uncertainties associated with market and other conditions and the satisfaction of customary closing conditions related to the proposed public offering and other risks that are described in Teknova’s most recent periodic reports filed with the Securities and Exchange Commission, including Teknova’s Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent Quarterly Reports on Form 10-Q, including the risk factors set forth in those filings. These forward-looking statements speak only as of the date hereof. Teknova disclaims any obligation to update these forward-looking statements, except as required by applicable law.

Reconciliation of Non-GAAP Financial Measures

Adjusted EBITDA is a non-GAAP financial measure that is not prepared in accordance with GAAP and that may be different from non-GAAP financial measures used by other companies. Our management believes that the use of this non-GAAP financial measure provides an additional tool for investors to use in evaluating ongoing operating results and trends of Teknova. This non-GAAP financial measure should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. Adjusted EBITDA is a non-GAAP financial measure equal to net loss, the most directly comparable financial measure based on GAAP, excluding interest expense, income tax expense, depreciation and amortization, and stock-based compensation expense.

The following is a reconciliation of net income, the most directly comparable GAAP financial measure to Adjusted EBITDA:

| ($ in thousands) | Three Months Ended September 30, 2026 (Estimated) |

| Net loss | $(3,694) - $(3,494 | ) |

| Add back: | | |

| Interest expense, net | (259 | ) |

| Provision for income taxes | 34 | |

| Depreciation expense | 1,302 | |

| Amortization of intangible assets | 287 | |

| EBITDA | $(1,812) - $(1,612 | ) |

| Other and non-recurring expenses: | | |

| Stock-based compensation expense | 612 | |

| Adjusted EBITDA | $(1,200) - $(1,000 | ) |

| | | |

Prompts

Alpha Teknova, Inc. (ticker TKNO), listed in United States.

ETFs Holding Alpha Teknova, Inc.

ETF Weight in ETF Shares Market value As of
DCOR 0.00% 2,742 $ 22.745K Nov 12, 2026
DFAS 0.00% 1,717 $ 14.243K Nov 12, 2026
AVSC 0.00% 5,493 $ 42.681K Nov 16, 2026